Saturday, January 17, 2026
  • Advertise
  • Recruitment
  • Contact us:
  • Register
Irish Pharmacy News
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
Irish Pharmacy News

Management of Sleep Disorders in Pharmacy

Mikeleigh by Mikeleigh
22 October 2020
in CPD
0
Management of Sleep Disorders in Pharmacy
Previous Post

Arthritis Ireland launches free online courses to support people during Covid-19

 Next Post

Vitamin D Deficiency in Ireland – Implications for COVID-19
Next Post
Vitamin D Deficiency in Ireland – Implications for COVID-19

Vitamin D Deficiency in Ireland – Implications for COVID-19

Leave a Reply

Your email address will not be published. Required fields are marked *

ALONE Urges Government to Reconsider Pharmacy Changes Including Blister Packs

ALONE Urges Government to Reconsider Pharmacy Changes Including Blister Packs

16 December 2025
Migraine Ireland launches the Irish Headache Society to advance migraine and headache care in Ireland.

Migraine Ireland Launches First Multidisciplinary Irish Headache Society

8 December 2025
Boots Ireland launches Common Conditions Service allowing pharmacists to prescribe for the first time.

Boots Ireland Unveils Groundbreaking Common Conditions Service, Empowering Pharmacists to Prescribe for the First Time

8 December 2025

RECOMMENDED NEWS

A new way to care for elderly people making 999 calls

A new way to care for elderly people making 999 calls

5 years ago
GSK plc has announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with Shingrix (Recombinant Zoster Vaccine or RZV). The final trial data demonstrate that RZV maintains efficacy against shingles for more than a decade in adults over 50. The data presented at the European Congress of Clinical Microbiology and Infectious Diseases (ESCMID) in Barcelona, Spain (27–30 April 2024) is based on the ZOSTER-049 study.1

New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade

2 years ago

HSE launches new Hepatitis C online information resource

7 years ago
Pharmacists Urged to Signpost Psoriasis Patients to New Research Study Examining Links with Psoriatic Arthritis

Pharmacists Urged to Signpost Psoriasis Patients to New Research Study Examining Links with Psoriatic Arthritis

2 years ago

test-sponsored-ad-jan-2026

Tweets by Irish_PharmNews

Quick links

  • About
  • Advertise
  • Careers
  • Contact us

Other info

  • Contact us
  • Register for Digital Magazines
  • Privacy Policy
  • About
  • Advertise
  • Careers
  • Contact us

© 2024 IPN

  • Login

    Forgot password? | Register

    Register

    Registration confirmation will be emailed to you.

    Login | Forgot password?

    Reset Password

    Please enter your username or email address. You will receive a link to create a new password via email.

    Login

Login

Register

Forgotten Password?

Register | Lost your password?
| Back to Login
No Result
View All Result
  • News
  • Learning
  • Other
    • Conferencing
    • Developments
    • Product News
    • Profiles
    • Research
  • Digital Magazines (IPN Online Issues Older Issue Tabs)
  • Awards

© 2024 IPN